,69-bis(methylenedioxy)-2-hydroxymethyl-29-methoxycarbonyl biphenyl] is a synthetic hepatoprotectant widely used in clinical practice, but resistance to this treatment is often observed. We found that the hepatoprotective effect of bicyclol was greatly compromised in female and castrated male mice. This study was to dissect the molecular basis behind the sex difference, which might underlie the clinical uncertainty. We compared bicyclol-induced hepatoprotection between male and female mice using acute liver damage models. Inducible knockout by the Cre/loxp system was used to decipher the role of heat shock transcription factor 1 (HSF1). Functional experiments, western blot, and histopathological analysis were used to determine the key causative factors which might antagonize bicyclol in female livers. HSF1 activation and heat shock protein 70 (Hsp70) expression, which were responsible for bicyclolinduced hepatoprotection, were compromised in female and castrated male livers. Compromised HSF1 activation was a result of HSF1 phosphorylation at serine 303, which was catalyzed by glycogen synthase kinase 3b (GSK3b). Testosterone was necessary for bicyclol to inhibit hepatic GSK3b activity. Administration of testosterone or GSK3b inhibitors restored bicyclol-induced protection in females. Bicyclol induces sex-specific hepatoprotection based on a sex-specific HSF1/Hsp70 response, in which testosterone and GSK3b play key roles. Because a lot of patients suffering from liver diseases have very low testosterone levels, our results give a possible explanation for the clinical variation in bicyclol-induced hepatoprotection, as well as practicable solutions to improve the effect of bicyclol.
Introduction
Bicyclol [4,49-dimethoxy-5,6,59 ,69-bis(methylenedioxy)-2-hydroxy-methyl-29-methoxycarbonyl biphenyl] is a synthetic hepatoprotectant and has been approved to treat liver injury in China since 2004. Clinical observations have proved that bicyclol treatment significantly decreases serum aminotransferase levels in hepatitis sufferers (Liu, 2009) . Bicyclol is also effective in the treatment of acute hepatic injury induced by other causes, such as alcohol, drugs, or ischemia/reperfusion injury (Zhao et al., 2008; Yao et al., 2009) . Meanwhile, no noticeable side effects have been observed during or after bicyclol treatment in the clinical setting.
Although bicyclol seems to be a promising therapeutic option for the treatment of hepatic damage, resistance to bicyclol treatment is frequently observed in clinical practice. It is frequently observed that bicyclol keeps serum aminotransferase at a very low level, although the histologic findings and clinical manifestations indicate ongoing liver damage. Moreover, bicyclol reduces alanine aminotransferase (ALT) levels to a much greater extent than aspartate aminotransferase (AST), resulting in a very high AST/ALT ratio.
Bicyclol-induced hepatic protection has been corroborated in various types of liver damage animal models. For example, acute liver damage induced by carbon tetrachloride (Liu et al., 2005) , acetaminophen (Hou et al., 2008) , concanavalin A (Bao and Liu, 2009) , and D-galactosamine (GalN)/lipopolysaccharide (LPS) can be ameliorated by bicyclol administration. Further studies demonstrated that bicyclol treatment resulted in hepatic activation of heat shock transcription factor 1 (HSF1), which stimulated heat shock protein (HSP) 27 and HSP70 expression Liu, 2008, 2009) . Moreover, the protective effects of bicyclol on mouse liver injury can be markedly compromised by quercetin, an inhibitor of heat shock protein biosynthesis, thus leading to the conclusion that the molecular basis of bicyclol-mediated protection against liver injury is the induction of hepatic heat shock proteins Liu, 2008, 2009) . After reviewing all the available literature on this subject, it is interesting and surprising to find that all of these studies were conducted in male animals. What happens, then, to the females?
To answer this question, in this study, we subjected both male and female mice to chemical toxicant or drug-induced liver damage, and surprisingly found that bicyclol had few The gross appearance of mouse livers at 6 (PBS groups) or 8 hours (Bic groups) after GalN/LPS intoxication. Only bicyclol-treated male livers had a relatively normal gross appearance. Serum ALT (C) and AST (D) concentrations at different time points after intoxication are shown (n = 4 per group). *P , 0.05 between PBS-and Bic-treated groups; **P , 0.05 between Bic-treated females and males. (E) Representative H&E-stained sections from normal livers and postintoxication livers harvested at 6 (PBS group) or 8 hours (Bic group) (original magnification 200Â). The livers from PBS-treated mice were harvested at 6 hours because the mice would not survive after that. Bic-treated livers were harvested at 8 hours after intoxication because hepatic damage in females would not become obvious until then.
Sex-Biased Hepatoprotection of Bicyclol effects on females. Mechanically, bicyclol-induced HSF1 activation and HSP induction were compromised in females, which was a result of HSF1 phosphorylation catalyzed by glycogen synthase kinase 3b (GSK3b).
Materials and Methods
Mice. The Cre/loxp recombination system was used to generate HSF1 -/-mice that have been described before (Le Masson et al., 2011) . Mice containing loxp-flanked HSF1 exons 2-4 (HSF1 loxp/loxp ) were a gift from Dr. Elisabeth S. Christians (University of Utah School of Medicine, Salt Lake City, UT). Mx1 promoter sequence-modified Cre recombinase genes (Mx1-Cre) were from the Jackson Laboratory (Bar Harbor, ME). After a mating of these two strains and a second mating of their progeny, mice that were homozygous for the HSF1 floxed allele and carried the Mx1-Cre transgene were generated (Mx1-Cre 
HSF1
loxp/loxp mice that had received injections of pIpC served as controls, and are referred to as HSF1 1/1 mice. Genomic DNA was isolated from tail biopsies, and genotyping was performed using polymerase chain reaction. The floxed and wild-type alleles were detected using the following primers: 59-CTAGTCAGTCCCTAGAGATGACCAG-39, 59-AAGCATAGCATCCT-GAAAGAGGTAC-39, and 59-GTTGTGGTCAGCTCCTGTC-39, which generated a 482-bp product in the floxed allele, 432-bp product in the wild type, and 324 bp in the knockout allele. Wild-type male and female C57BL/6 mice, 8-12 weeks old (18-26 g), were purchased from Shanghai SLAC Co. Ltd. (Shanghai, China). A total of 456 male mice and 552 female mice were used in this study.
The animals were handled in accordance with standard use protocols, animal welfare regulations, and the institutional guidelines of Shanghai Jiaotong University School of Medicine and the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council). All the procedures described were approved on June 25th, 2011, by the Animal Use and Care Committee of Shanghai Jiaotong University School of Medicine (approval number: SYKX-2011-0039).
Determination of Lethality. Survival was observed in some groups after GalN/LPS intoxication. The number of survival mice was counted and recorded every half hour from 4 to 12 hours after the GalN/LPS injection, then every 12 hours until the seventh day after intoxication. No deaths were observed after the third day, so mice that survived more than 72 hours were considered to survive indefinitely. If an animal was considered possibly morbid, the condition of the animal was monitored every 15 minutes. The presence of morbid symptoms was determined by an experienced observer with no prior information regarding the treatments and genetic background of the animals. Animals were considered morbid if they were severely immobile, hunched in posture, experiencing severe hypothermia, and/or unresponsive to noise. After signs of morbidity were detected, death was considered unavoidable and the animal was euthanized under anesthesia with isoflurane inhalation. After that, a laparotomy was conducted, and liver failure was confirmed by macroscopic and microscopic examination. Animals that survived to the seventh day were also euthanized under anesthesia, and the successful recovery of hepatic function was confirmed by serum ALT/AST analyses and macroscopic/microscopic examination.
Western Blot Analysis. Harvested liver samples were homogenized and lysed with cell lysis buffer, which contained one protease inhibitor cocktail tablet per 10 ml of Lysis Reagents (Complete; Roche, Indianapolis, IN). Solutions were then clarified by centrifugation (25 minutes at 16,000g). Solubilized proteins were then resolved on a 10% SDSpolyacrylamide gel and transferred to nitrocellulose membranes (Whatman/GE Life Sciences, Little Chalfont, UK). After being blocked with LI-COR blocking buffer (LI-COR Biosciences, Lincoln, NE), blots were incubated with anti-Hsp70 (1:500; Cell Signaling Technology, Inc., Danvers, MA), anti-Cleaved Caspase 3 (1:1000; Cell Signaling Technology), anti-GSK3b (1:1000; Abcam, Cambridge, MA), anti-GSK3b pSer9 (1:500; Abcam), anti-GSK3b pTyr216 (1:500; Abcam), and anti-b-actin antibodies (1:2000; Santa Cruz Biotechnology, Inc., Dallas, TX). After incubation with IRDye800 secondary antibodies (1:10,000; LI-COR Biosciences), membranes were washed three more times in Tris-buffered saline/0.05% Tween 20. The blot was visualized using an Odyssey infrared imaging system (LI-COR Biosciences). Samples were corrected for background and quantified using Odyssey software. Hsp70, caspase 3, and GSK3b expression levels were normalized to b-actin.
To detect HSF1, nuclear extracts were isolated from harvested liver tissues using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Inc., Waltham, MA) supplemented with Complete Protease Inhibitor Cocktail Tablets (Roche). Nuclear protein indicates the control samples from mice that received bicyclol (Bic)/PBS treatment but were sacrificed before GalN/LPS intoxication. The mean value obtained from the PBS/female/con group was arbitrarily defined as 1. There were four mice at every time point in each group, and data are expressed as the mean 6 S.D. *P , 0.05 between Bic/male and other groups; **P , 0.05 between Bic-treated males and females; # P , 0.05 between PBS-and Bic-treated groups.
fractions were electrophoresed on 10% SDS-PAGE under reducing conditions and transferred to a nitrocellulose membrane (Whatman) by standard procedures. Membranes were blocked with LI-COR blocking buffer. Membranes were then incubated with the same blocking solution containing rabbit polyclonal primary antibodies against HSF1 (1:1000; Cell Signaling Technology, Inc.) and phospho-HSF1 (pSer303, 1:500; Abcam). After washing, membranes were incubated at room temperature for 1 hour in Tris-buffered saline/0.05% Tween 20 buffer with IRDye800 secondary antibodies, and blots were developed as described earlier. All values were normalized to a loading control TATA binding protein (1:2000; Abcam) and expressed as the fold increase relative to control.
ALT/AST Determination. Arterial blood was collected by direct puncture of arteriae aorta under anesthesia with isoflurane inhalation. Serum levels of ALT and AST were measured with a standard clinical automatic analyzer (Dimension Xpand; Siemens Dade Behring, Munich, Germany).
Liver Histopathology. Hepatic samples were fixed in 10% neutral buffered formalin overnight, dehydrated, embedded in paraffin, sectioned, Fig. 3 . Bicyclol lost hepatoprotective effect in castrated males. Male mice were subjected to castration, followed by bicyclol (Bic) treatment and GalN/LPS intoxication. (A) Survival of mice after intoxication (n = 20 per group). Bicyclol treatment led to a significant survival advantage only in sham-operated mice by Kaplan-Meier analysis (log-rank test, P , 0.05). (B) Representative immunoblotting results of protein expression of Hsp70 and active caspase 3 in postintoxication livers harvested at 6 (PBS group) or 8 hours (Bic group). (C) Protein bands were quantified and normalized to b-actin. For Hsp70, the mean value obtained from PBS-treated control mice was arbitrarily defined as 1. For caspase 3, the mean value obtained from PBS-treated control mice was arbitrarily defined as 10. There were four mice in each group, and data are expressed as the mean 6 S.D. *P , 0.05 versus other groups. For Hsp70, the mean value obtained from PBStreated control mice was arbitrarily defined as 1. For caspase 3, the mean value obtained from PBS-treated control mice was arbitrarily defined as 10. There were four mice in each group, and data are expressed as the mean 6 S.D. *P , 0.05 versus the single agent groups.
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and stained with H&E. For histologic analysis, sections were evaluated in a blinded manner by a pathologist. At least three fields per section were evaluated.
Drugs and Experimental Design. Bicyclol (Beijing Union Pharmaceutical Plant, Beijing, China) was suspended in phosphatebuffered saline (PBS) to produce injectable suspensions and was administered by gavage three times (300 mg/kg each time) in 24 hours. One hour after the last administration, the mice were subjected to intraperitoneal injection of GalN (700mg/kg; Sigma-Aldrich, St. Louis, MO) and LPS (10 mg/kg; from Escherichia coli serotype 055:B5; SigmaAldrich) to induce acute liver failure. Additional animals in control groups received vehicle (PBS) orally, followed by GalN/LPS injection. In other groups, carbon tetrachloride (0.4% diluted in olive oil; SigmaAldrich) was administered intraperitoneally at a single dose of 10 ml/kg at 1 hour after the last administration of bicyclol. Some mice received acetaminophen (dissolved in PBS; Sigma-Aldrich) intraperitoneally at a single dose of 300 mg/kg at 1 hour after the last administration of bicyclol. In separate groups, bicyclol was administered once (300 mg/kg) at 1 hour after the injection of GalN/LPS or acetaminophen. Dosage of bicyclol was used in accordance with previously published work (Wang and Li, 2006; Bao and Liu, 2009 ). Animals were killed at different time points after intoxication by exsanguination, to obtain blood and liver samples for further analyses. Some male mice were castrated 3 weeks before they were subjected to bicyclol administration and GalN/LPS intoxication. In brief, mice were anesthetized with isoflurane inhalation (0.5-2.0%), and the flow rate of the inhaled agent was adjusted as required to maintain appropriate depth of anesthesia, which continued until the closure of the skin wound. After anesthesia was induced, both testes were exposed and sectioned. Analgesia was induced using bupivacaine (0.5%), a long-acting local analgesic, immediately after surgery and only once. Several drops of bupivacaine were dripped on the suture line before the closure of the skin wound. All of these efforts were made to minimize suffering. The mice in the sham-operation group were subjected to the same procedures, except that no testis was resected.
Some female mice were treated with a single injection of long-termrelease testosterone undecanoate (Ts; 12.5 mg in 0.1 ml per mouse; Xianju Pharmaceutical Co., Ltd., Zhejiang, China) by subcutaneous injection in the neck, and 14 days later, the mice were subjected to bicyclol treatment and GalN/LPS intoxication. Anastrozole (Ana; 25 mg/mouse; Sigma-Aldrich) was administered subcutaneously once daily for 14 consecutive days, and was followed by GalN/LPS treatment. Some female mice were treated with GSK3b inhibitors. Lithium chloride solution (150 mg/kg; Sigma-Aldrich), SB216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; dissolved in dimethylsulfoxide; 10 mg/kg; Sigma-Aldrich), or tideglusib (dissolved in dimethylsulfoxide; 10 mg/kg; Cayman Chemical, Ann Arbor, MI) was administered intraperitoneally three times (at the same time point as bicyclol) in 24 hours, followed by GalN/LPS intoxication.
Statistical Analysis. All values were reported as the mean 6 S.D. Data were analyzed with a one-way analysis of variance with subsequent Student-Newman-Keul's test or Student's t test where applicable. Statistical significance was set at P , 0.05. 
Results
There Was a Great Sex Difference in Bicyclol-Induced Hepatoprotection. In the study of bicyclol-induced hepatoprotection, we used a previously described protocol (Wang and Li, 2006) . Three doses of bicyclol (300 mg/kg) were administered orally to mice within 24 hours. One hour after the last dose of bicyclol, the mice were subjected to intraperitoneal injection of GalN (700 mg/kg)/LPS (10 mg/kg). Without bicyclol treatment, deaths of mice (male or female) occurred at 5.5 hours, and all mice died within 2 hours thereafter. Bicyclol treatment led to a survival rate of over 90% in male mice, but showed few protective effects in female mice (Fig. 1A) . Blood aminotransferases (ALT and AST) increased in female mice despite treatment with bicyclol, and all of them died within 10 hours, thereby precluding further time-course studies (Fig. 1, C and D) . It is worth noting that the elevation of serum ALT was not very significant and was not comparable with AST, even at 9 hours after the intoxication, and the mice were going to die within minutes. The macroscopic and microscopic pathologic findings were consistent and are shown in Fig. 1, B and E. The sex difference remained when bicyclol was given after GalN/LPS intoxication (Supplemental Fig. 1 ), or in other liver injury models such as acetaminophen (Supplemental Fig. 2 ) and carbon tetrachloride (Supplemental Fig. 3 ). These findings indicate that only males are protected against acute liver damage by bicyclol, which leads to a high AST/ALT ratio and no protection in females.
Bicyclol Induced Hsp70 Expression in Male, but Not Female, Livers. Previous studies Liu, 2008, 2009) have demonstrated that bicyclol induces hepatic HSPs, which constitute the molecular basis of the hepatoprotection afforded by bicyclol. So we sought to determine the role of a key heat shock protein, Hsp70, in the sex difference of bicyclol-induced hepatoprotection. At different time points after GalN/LPS intoxication, livers were harvested and total protein was subjected to immunoblotting analysis. A representative result was shown in Fig. 2 . In line with the serum and histologic findings, bicyclol induced Hsp70 expression in male livers but failed to do so in females. Cleaved caspase 3, a key mediator of mammalian cell apoptosis and an indicator of liver injury in this setting, was negatively related to the expression of Hsp70.
Bicyclol Lost Hepatoprotective Effect in Castrated Male Mice, but Protected Female Mice when Administered Together with Exogenous Testosterone or Anastrozole. To further determine if sex hormones were behind the sexual dimorphism in bicyclol-induced hepatic protection, Fig. 6 . The effect of bicyclol on nuclear HSF1 accumulation and phosphorylation (Ser303) in male and female livers. (A) Bicyclol (Bic) was administered by gavage three times (300 mg/kg each time) in 24 hours. One hour after the last administration, the livers were harvested and nuclear total HSF1 and phosphorylated HSF1 (Ser303) levels were evaluated by western blot analysis, and codetection of TATA binding protein (TBP) was performed to assess equal loading. (B) HSF1 protein bands were quantified and normalized to TBP. Phosphorylated HSF1 protein bands were quantified and normalized to total HSF1. Bicyclol induced nuclear HSF1 accumulation in both male and female livers, but an increased phosphorylated HSF1 (Ser303) level was observed only in females. The mean value obtained from PBS-treated male mice was arbitrarily defined as 1. There were four mice in each group, and data are expressed as the mean 6 S.D. *P , 0.05 versus PBS-treated mice; **P , 0.05 versus Bic-treated females. (C) Administration of Ts to females attenuated bicyclol-induced HSF1 (pSer303) levels. (D) pHSF1 protein bands were quantified and normalized to HSF1. The mean value obtained from Bic-treated male mice was arbitrarily defined as 1. There were four mice in each group, and data are expressed as the mean 6 S.D. **P , 0.05 versus Bic-treated female mice. (E) Administration of GSK3b inhibitors (SB216763 and tideglusib) to females attenuated bicyclol-induced HSF1 (pSer303) levels. (F) pHSF1 protein bands were quantified and normalized to HSF1. The mean value obtained from Bic-treated female mice was arbitrarily defined as 10. There were four mice in each group, and data are expressed as the mean 6 S.D. **P , 0.05 versus Bic-treated females.
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we removed testicles of male mice, and subjected them to GalN/LPS intoxication 3 weeks later. Although sham-operated mice were protected as expected, bicyclol failed to induce hepatic Hsp70 and protect the castrated males (Figs. 1E and 3) . We next administered Ts to female mice, and subjected the mice to GalN/LPS intoxication 2 weeks later. We also explored the effect of Ana, an aromatase inhibitor that prevented estrogen synthesis from androgens. Ts or Ana alone did not induce hepatic Hsp70 expression and hepatoprotection, but when administered with bicyclol, the drug combination showed outstanding synergistic effects and protected females (Figs. 1E  and 4) .
HSF1 Was Necessary to the Hepatoprotective Effect of Bicyclol in Males and Testosterone-Treated Females.
To figure out what was behind the sexual dimorphism of bicyclolinduced Hsp70 expression and hepatoprotection, we first used the HSF1 2/2 mice to explore the role of HSF1 in this setting. Hsp70 is one of the inducible heat shock proteins that play essential roles in protecting cells against stress (Hu et al., 2007) , and mammalian HSF1, a protein well known as the major transcriptional regulator of the heat shock response, is required for inducible HSP expression (McMillan et al., 1998) . Systematic knockout of HSF1 leads to multiple cellular and developmental defects, decreased body weight, and postnatal growth retardation (Xiao et al., 1999) . So we used the Cre/loxp recombination system and an interferon-responsive Mx1-Cre transgene, a method of gene targeting that allowed the inducible inactivation of a target gene in adult mice (Kuhn et al., 1995 ) were subjected to injections of the interferon inducer pIpC, and the successful disruption of the target gene was confirmed by immunoblotting analysis (Fig. 5A) . Although bicyclol showed remarkable protection in HSF1 1/1 control mice, it failed to induce Hsp70 expression and protect against liver failure in HSF1 2/2 mice (Fig. 5, B-D) . These results indicate that the effect of bicyclol is based on HSF1, and suggest that the variation in HSF1 activity after bicyclol treatment may be responsible for the practice variation and clinical uncertainty in the outcome of the pharmacologic treatment.
Bicyclol Induced a Suppressive Phosphorylation (Serine 303) of HSF1 in Female Livers, Which Could Be Diminished by Simultaneous Administration of Testosterone or GSK3b Inhibitors. Phosphorylation of HSF1 on serine 303 by GSK3b was reported to mediate the negative control exerted on the activation domains of HSF1 and inhibit transcriptional activation of heat shock genes (Chu et al., 1996) . To explore the possible role of the phosphorylated serine 303 on bicyclol-induced transcriptional activation of HSF1, both male and female mice were given three doses of bicyclol, and 1 hour after the last dose, the livers were harvested and subjected to immunoblotting analysis. As shown in Fig. 6A , bicyclol induced equal amounts of nuclear HSF1 accumulation in both sexes. However, serine 303 was markedly phosphorylated only in female livers, which could be attenuated by simultaneous administration of testosterone (Fig. 6B ). SB216763 and tideglusib (both are GSK3b inhibitors, Fig. 6C ) also significantly decreased HSF1 phosphorylation, indicating that serine 303 phosphorylation and the repression of HSF1 activity in females were a result of GSK3b catalytic activity.
Testosterone Was Necessary for Bicyclol to Inhibit Hepatic GSK3b Activity. The aforementioned results implied that bicyclol did induce nuclear HSF1 accumulation in female livers, but failed to induce full activation of heat shock response because of GSK3b-catalyzed HSF1 phosphorylation. To compare hepatic GSK3b activity between males and females, liver samples were subjected to immunoblotting analysis using two phosphospecific GSK3b antibodies to probe inactivated phosphorylated serine 9 and activity-enhanced phosphorylated tyrosine 216, respectively. As shown in Fig. 7 , GSK3b was constitutively active in livers of both sexes. Bicyclol treatment inhibited GSK3b activity in male livers. However, inhibition of GSK3b in female livers could be observed only when administered with bicyclol/testosterone.
Simultaneous Administration of GSK3b Inhibitors and Bicyclol Protected Female Mice against GalN/LPSInduced Liver Failure. The aforementioned results suggested the sexual dimorphism in bicyclol-induced hepatoprotection was based on bicyclol-induced sexual dimorphism in hepatic GSK3b activity. If that was true, GSK3b inhibitors and bicyclol should have a synergistic effect in females. So we used three different GSK3b inhibitors, lithium chloride solution, SB216763, and tideglusib, which were administered with bicyclol to test the hypothesis. Although these drugs themselves had few effects on GalN/LPS-induced liver damage, any one of the three produced a remarkable synergistic effect with bicyclol in the induction of hepatic Hsp70 expression and hepatoprotection in females (Fig. 8) . Fig. 7 . The effect of bicyclol and Ts on hepatic GSK3b activities. (A) Some mice had been pretreated with Ts 2 weeks before. Bicyclol (Bic) was administered to male and female mice three times in 24 hours. One hour after the last administration, the livers were harvested and GSK3b (total, pSer9, pTyr216) levels were evaluated by western blot analysis, and codetection of b-actin was performed to assess equal loading (n = 6 for each group). (B) pGSK3b bands were quantified and normalized to total GSK3b. The statistical significance was indicated. *P . 0.05 versus females without treatment.
Discussion
Protecting the liver from various types of injury remains a major challenge of pharmacotherapy, considering that impairment of the liver is a worldwide problem resulting from a lot of etiologies. The fact that the number of hepatoprotective drugs successfully used in clinical practice is actually very limited accents the clinical importance of bicyclol, a synthetic hepatoprotectant which has been demonstrated to protect against hepatotoxicant-induced, immune-related, or ischemiamediated liver injury. Moreover, in clinical trials and application, bicyclol shows a certain level of activity to inhibit hepatitis virus replication (Liu, 2009) . Studies also indicate that bicyclol has the chemopreventive potential for liver carcinogenesis induced by carcinogens (Zhu et al., 2006; Sun et al., 2012) . The reported experimental and clinical results indicate that more extensive comparative experimental studies with bicyclol should be conducted to dissect its molecular basis, and if possible, to improve its clinical effects. 
Sex-Biased Hepatoprotection of Bicyclol
In the current study, we reconfirmed the outstanding protective effect afforded by bicyclol in males. But in female and castrated male mice, bicyclol had few effects on ongoing liver damage, although the serum ALT level was greatly reduced. This was true in all types of liver damage models we tested ( Fig. 1; Supplemental Figs. 1-3) . Such contradictory outcomes can be easily and frequently observed in the clinical setting. Our finding is very important, not only because a lot of females suffer from hepatic damage and are in need of efficient treatment, but also because hypogonadal testosterone levels are common in males, which may invalidate bicyclol treatment in male patients, too. It has been reported that low testosterone levels in men occur with increasing age, and are frequently observed in the primary care setting, particularly in patients with obesity, metabolic syndrome, and acute inflammation (Schneider et al., 2009 ). All of these conditions can be related to liver injury, which leads to the application of hepatoprotectants. Liver diseases and cancer are associated with very low testosterone levels (Grossmann et al., 2012) . For example, Child-Pugh grades B and C hepatic insufficiency in men results in a significant reduction of both total and free testosterone levels (Zifroni et al., 1991) . Alcohol administration also results in acute suppression of testosterone in men (Vatsalya et al., 2012) , and patients with alcoholic cirrhosis show hypogonadism and feminization associated with sex hormone imbalance due to enhanced aromatization of testosterone (Pignata et al., 1997) . Low serum testosterone is also a special feature of hepatocellular carcinoma (Lampropoulou-Karatzas et al., 1993) . Since so many users of bicyclol are possibly hypogonadal, it is not difficult to understand why resistance to bicyclol treatment is frequently observed in clinical practice.
One of the major findings of this study is that bicyclol induces sex-specific hepatoprotection based on a sex-specific HSF1/Hsp70 response, in which androgen matters a lot. It is interesting because sex-biased activation of hepatic HSF1 by bicyclol may underlie the confusing observations in clinical practice. Sex-biased HSF1 activation and heat shock response have been reported before. For example, nuclear HSF1 accumulation and synthesis of Hsp70 were only observed in neurons of testosterone-treated rats, but not in estradioltreated rats (Papasozomenos and Papasozomenos, 2008) . Synthesis of Hsp70 is regulated by HSF1, which is the master regulator of the heat shock response mediating the inducible rapid, massive, transient, and almost exclusive transcription of heat shock protein genes (Rabindran et al., 1991) . Previous reports Liu, 2008, 2009 ) have suggested that HSF1 was the key molecular mediator of the pharmacologic effects of bicyclol. In the current study, by using HSF1 2/2 mice, we were able to substantiate the point. HSF1 activation is a multistep and tightly regulated process. In mammalian cells, heat shock induces a transition of the HSF1 protein from monomer to trimer, which is the key step toward nuclear translocation and DNA binding of HSF1. After trimerization, the transcriptional activity of HSF1 is correlated with increased phosphorylation at a number of serine residues (Rabindran et al., 1993) . For example, phosphorylation of serine 230 promotes inducible transcriptional activity of HSF1 (Holmberg et al., 2001 ). On the contrary, sequential phosphorylation of serine 307 and 303 represses the activity of HSF1 (Chu et al., 1996) . In the current study, we found that bicyclol-induced nuclear HSF1 accumulation was comparable between males and females, suggesting that HSF1 trimerization and nuclear translocation might not be responsible for its sexual dimorphism. We then evaluated the phosphorylation of two serine residues of HSF1 (pSer230 and pSer303) and found that there was no difference in hepatic pHSF1 (Ser230) between males and females after bicyclol treatment (data not shown). However, the results from pSer303 detection showed a significant difference between males and females. Subsequent studies revealed that hepatic activity of GSK3b, the kinase responsible for phosphorylation of Ser303 in HSF1 (Chu et al., 1996) , was influenced by bicyclol. As shown in Fig. 7 , GSK3b was constitutively active in both male and female livers, but its activity was inhibited by bicyclol treatment in males or testosterone-treated females, which was consistent with the observation of reduced pHSF1 (S303) expressions in these mice (Fig. 6) . The schematic outline of how bicyclol and testosterone influenced the heat shock response in the liver is presented in Fig. 9 . It was previously reported (Papasozomenos and Shanavas, 2002) that testosterone prevented the heat shock-induced overactivation of GSK3b in nerve tissues, which was consistent with our findings in hepatic GSK3b activities. Although further study is clearly required to clarify how testosterone is involved in GSK3b inactivation, these experiments indicate that bicyclol induces hepatic HSF1 activation because 1) it induces nuclear HSF1 accumulation, an effect independent on testosterone, and 2) it inhibits GSK3b activity to promote HSF1 transcriptional activity, an effect dependent on testosterone. Our observations are consistent with previous reports indicating that GSK3b negatively regulates both DNA-binding and transcriptional activities of HSF1 (Xavier et al., 2000) and inhibition of GSK3b ameliorates GalN/LPS-induced liver injury in males (Chen et al., 2012) . The dosage of GSK3b inhibitors we used had few effects in the prevention of acute liver failure in females, but led to remarkable Hsp70 induction and hepatoprotection when administered with bicyclol. These Fig. 9 . Schematic outline of how bicyclol and testosterone influence the heat shock response in the liver. When bicyclol is administered to females, the constitutively activated GSK3b phosphorylates HSF1 at serine 303, thus inactivates it and prevents the heat shock response. By contrast, when bicyclol is administered to males or administered together with testosterone, it not only increases the nuclear HSF1 protein level, but also inactivates GSK3b by phosphorylating serine 9 and dephosphorylating tyrosine 216. Without the catalyzing activity of GSK3b, ser303 of HSF1 is dephosphorylated, resulting in the full activation of HSF1 and heat shock response.
observations further confirmed our conclusion that GSK3b was implicated in the regulation of hepatic HSF1 activity and pharmacological action of bicyclol.
Our results demonstrate that the poor effects of bicyclol in female or castrated male mice can be markedly improved by the simultaneous administration of testosterone, aromatase inhibitors, or GSK3b inhibitors, which produce a synergistic and remarkable promoting effect with bicyclol to activate HSF1. These findings are of clinical importance because testosterone, aromatase inhibitors, or GSK3b inhibitors are now in clinical use, and the protocol for drug combination can easily be applied to the clinical setting, although further studies, including monitoring of side effects of the new multidrug protocol, are clearly required. Our findings about the enhanced activation of HSF1 by testosterone and the underlying mechanisms are worth further study because HSF1 and HSPs constitute the molecular basis of many other drugs. Further studies targeting the relationship between testosterone and GSK3b might help to develop new hepatic protectants which are not sex-biased. 
